Current Report Filing (8-k)
March 30 2023 - 8:51AM
Edgar (US Regulatory)
0000946644
false
0000946644
2023-03-28
2023-03-28
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report March 28, 2023
AIM
IMMUNOTECH INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-27072 |
|
52-0845822 |
(state
or other jurisdiction |
|
(Commission |
|
(I.R.S.
Employer |
of
incorporation) |
|
File
Number) |
|
Identification
No.) |
2117
SW Highway 484, Ocala FL |
|
34473 |
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (352) 448-7797
AIM
Immunotech Inc.
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol |
|
Name
of each exchange on which registered |
Common
Stock, par value $0.001 per share |
|
AIM |
|
NYSE
American |
Item
5.02 |
Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
(d)
Election of Directors
On
March 30, 2023,
AIM ImmunoTech Inc. (the “Company”) issued a press release announcing the appointment of Nancy Bryan to its Board of Directors
(the “Board”), effective March 28, 2023, to serve until the Company’s 2023 Annual Meeting of Stockholders. The Board
also has appointed her to the Audit, Corporate Governance and Nomination and Executive Committees. A copy of the press release is furnished
herewith as Exhibit 99.1.
The
Board has determined that Ms. Bryan meets the independence standards adopted by the Board in compliance with Item 407(a) of Regulation
S-K. Ms. Bryan does not have (i) any arrangement or understanding with any other person pursuant to which she was appointed as a director,
or (ii) any family relationship with any director or executive officer of the Company or any person nominated or chosen by the Company
to become a director or executive officer. Ms. Bryan does not have any direct or indirect material interest in any transaction required
to be disclosed pursuant to Item 404(a) of Regulation S-K.
Ms.
Bryan is the President and CEO of BioFlorida. In this role, she leads the development and execution of strategies to strengthen Florida’s
life sciences industry and advance innovative products and technologies that improve lives. She has 25 years of experience in the life
sciences in commercial positions of increasing responsibility involving primary care, biologics and specialty markets. Her experience
began with major pharmaceutical companies (MERCK, GlaxoSmithKline) and progressed to executive leadership positions in specialty pharmaceuticals
and smaller, start-up biotech companies (Indevus Pharmaceuticals, NPS Pharmaceuticals). She has served on executive leadership teams
and played a key role in companies’ successes including marketing, sales, business development, financing initiatives and investor
and PR communications. Throughout her career, Ms. Bryan has developed, launched and commercialized many products including: blockbusters
(Zantac, Levitra), major biologics (Tysabri) and orphan drugs for rare diseases (Valstar for bladder cancer, Supprelin LA for central
precocious puberty) and has established franchises in a wide variety of therapeutic areas including: Oncology, Anti-infectives, GI and
Autoimmune (MS,CD).
Ms.
Bryan earned a BA in Economics from the University of Virginia and an MBA from Columbia University. Academic honors include Phi Beta
Kappa and Beta Gamma Sigma.
Ms.
Bryan will be compensated for being a director and serving on committees in the same manner as all directors.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
AIM
IMMUNOTECH INC. |
|
|
|
March
30, 2023 |
By: |
/s/
Thomas K. Equels |
|
|
Thomas
K. Equels, CEO |
AIM ImmunoTech (AMEX:AIM)
Historical Stock Chart
From Mar 2024 to Apr 2024
AIM ImmunoTech (AMEX:AIM)
Historical Stock Chart
From Apr 2023 to Apr 2024